Oligonucleotide Drugs for Transthyretin Amyloidosis.

@article{Buxbaum2018OligonucleotideDF,
  title={Oligonucleotide Drugs for Transthyretin Amyloidosis.},
  author={Joel N. Buxbaum},
  journal={The New England journal of medicine},
  year={2018},
  volume={379 1},
  pages={
          82-85
        }
}
  • J. Buxbaum
  • Published 4 July 2018
  • Medicine, Biology, Psychology
  • The New England journal of medicine
In this issue of the Journal, Adams et al.1 and Benson et al.2 report the results of two randomized, double-blind, controlled trials testing the therapeutic efficacy of two different chemically mod... 

Figures from this paper

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
TLDR
Inotersen, a 2′-O-methyoxyethyl-modified antisense oligonucleotide, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study.
Emerging Therapies for Transthyretin Cardiac Amyloidosis
TLDR
Understanding the recent and upcoming clinical trials for transthyretin amyloidosis will be important for improving the management of this challenging disease.
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
  • Junyi Yang
  • Biology, Medicine
    Expert review of clinical pharmacology
  • 2019
TLDR
Patisiran can significantly reduce the TTR level and improve patient’s neuropathy and quality of life and the common adverse reactions were upper respiratory tract infections and infusion-related reactions.
Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis.
TLDR
Inotersen is a second-generation antisense oligonucleotide with 2'-O-methoxyethyl modification designed to bind to the 3' untranslated region of the transthyretin mRNA in the nucleus of the liver cells, impeding the progression of the disease.
Recommendations for addressing the translational gap between experimental and clinical research on amyloid diseases
TLDR
Recommendations include improving cross-cultural communication between basic science and clinical research, increasing the influence of scientific societies and journals, improving the dissemination of negative results, and strengthening the ethos of science.
Fatal TTR amyloidosis with neuropathy from domino liver p.Val71Ala transplant
TLDR
A domino liver recipient who died of respiratory failure from transplanted p.Val71Ala amyloidosis is described and oligonucleotide drugs that reduce circulating TTR are approved.
Amiloidosi da transtiretina (ATTR): l’altra faccia della medaglia
TLDR
Tafamidis, a TTR-stabilizer that has recently proved to be effective in cardiac forms of both ATTRm and ATTRwt, is now ready for clinical use and drugs silencing the TTR messenger RNA should soon be available for treatment.
Cardiac Amyloidosis: A Review of Current Imaging Techniques
TLDR
Key radiological features of CA are discussed, focusing on the two most common types; immunoglobulin light chain (AL) and transthyretin (ATTR) CA, highlighting recent advances in imaging techniques particularly in respect of their clinical application and utility in diagnosis of CA as well as for tracking disease change over time.
...
...

References

SHOWING 1-10 OF 10 REFERENCES
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
TLDR
No significant changes were reported in this trial even though transthyretin (TTR) was stabilized in all patients receiving Tafamidis, but various methodologic aspects may have influenced the results.
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
BACKGROUND Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves and the heart. A therapeutic approach mediated by RNA interference
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
TLDR
Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
TLDR
Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life.
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
TLDR
Long-term survival after Ltx, especially for early-onset TTR Val30Met patients, is excellent, and the risk of delaying Ltx by testing alternative treatments, especially in early-ONSet T transthyretin (TTR) amyloidosis patients, requires consideration.
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
  • E. Ackermann, Shuling Guo, B. Monia
  • Biology
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • 2016
TLDR
Nonclinical and clinical results support the ongoing Phase 3 development of IONIS-TTRRx in patients with ATTR amyloidosis, a 2nd-Generation 2′-O-(2-methoxyethyl) modified “2′-MOE” antisense oligonucleotide (ASO) that targets the TTR RNA transcript and reduces the levels of the T TR transcript through an RNaseH1 mechanism of action.
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
TLDR
There is no evidence that 2′MOE ASOs alter platelet function, as measured by the lack of clinically relevant bleeding in the presence or absence of other drugs that alter Platelet function and/or number and by the results from trials conducted with the factor XI (FXI) ASO.
Patisir - an , an RNAi therapeutic , for hereditary transthyretin amyloido
  • N Engl J Med
  • 2018